Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase NA 1

Status

Terminated 2Recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 6Gastrointestinal 1

Conditions

Breast Neoplasms 549Carcinoma, Non-Small-Cell Lung 506Prostatic Neoplasms 335Colorectal Neoplasms 268Multiple Myeloma 267Neoplasms 259Leukemia, Myeloid, Acute 218Squamous Cell Carcinoma of Head and Neck 213Lung Neoplasms 206Neoplasm Metastasis 204Carcinoma, Hepatocellular 197Triple Negative Breast Neoplasms 172Melanoma 172Pancreatic Neoplasms 171Recurrence 153Ovarian Neoplasms 151Lymphoma 140Sarcoma 132Glioblastoma 132Brain Neoplasms 132Head and Neck Neoplasms 126Carcinoma, Renal Cell 126Leukemia, Lymphocytic, Chronic, B-Cell 125Stomach Neoplasms 123Lymphoma, Large B-Cell, Diffuse 123Rectal Neoplasms 106Precursor Cell Lymphoblastic Leukemia-Lymphoma 104Uterine Cervical Neoplasms 101Urinary Bladder Neoplasms 101Myelodysplastic Syndromes 101

Interventions

Fulvestrant 3Letrozole 2tusamitamab ravtansine 1trastuzumab deruxtecan 1sacituzumab govitecan 1ribociclib 1pegfilgrastim 1exemestane 1abemaciclib 1Tamoxifen 1Paclitaxel 1Gemcitabine 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Breast Cancer Metastatic × 1 year × Clear all
NCT06750484 2026-05-06

Trial of Trastuzumab Deruxtecan in Previously Treated HER2

Yale University

Phase 2 Recruiting
40 enrolled
Breast

Breast Cancer Metastatic

NCT04059484 2026-02-24

AMEERA-3

Sanofi

Phase 2 Terminated
367 enrolled 30 charts
Breast

Breast Cancer Metastatic

NCT06849947 2025-12-24

Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer

Samsung Medical Center

Phase 2 Not yet recruiting
272 enrolled
Breast

Breast Cancer Metastatic

NCT04603183 2025-12-12

ABIGAIL

MedSIR

Phase 2 Completed
162 enrolled
Breast

Breast Cancer Metastatic

NCT04659603 2025-10-01

CARMEN-BT01

Sanofi

Phase 2 Terminated
50 enrolled 20 charts
BreastGastrointestinal

Breast Cancer Metastatic

NCT06616987 2025-08-28

Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer

Samsung Medical Center

Phase 2 Recruiting
40 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡